Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australia's TGA designates three orphan drugs

This article was originally published in Scrip

Executive Summary

Australia's Therapeutics Goods Administration (TGA) has designated three new orphan drugs. These are: Actelion's Zavesca (miglustat) capsules, for the treatment of Niemann-Pick disease type C, designated on July 8th; Ipsen's Increlex (mecasermin injection 10mg/ml in 40mg vial), for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency (severe primary IGFD), designated on July 1st; and Celgene's Vidaza (azacytidine) in a powder for suspension for injection, for the treatment of myelodysplastic syndrome, designated on June 17th.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts